Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Nasdaq Bear Market: 5 Fantastic Growth Stocks You'll Regret Not Buying On the Dip
05:06am, Saturday, 06'th Aug 2022
These transformative growth stocks are begging to be bought following a 34% peak decline in the Nasdaq.
Exelixis Needs To Move Away From Its Overdependence On Cabozantinib
06:46am, Wednesday, 03'rd Aug 2022
Cabo is a blockbuster drug, but there are potential headwinds. EXEL needs to find other assets and move them to late stages.
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
01:55pm, Monday, 01'st Aug 2022
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.
3 Stocks That Are Fantastic Deals Right Now
05:55am, Thursday, 28'th Jul 2022
These supercharged growth stocks can make investors rich over the long haul.
2 Biotech Stocks to Help Recession-Proof Your Portfolio
10:45am, Friday, 22'nd Jul 2022
These companies' shares have outpaced the market and other biotech stocks this year.
1 Reason to Buy Exelixis Stock, and 1 Reason to Sell
10:15am, Friday, 22'nd Jul 2022
Some say Exelixis is a one-trick pony -- but it is a pretty good trick.
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
01:06pm, Tuesday, 12'th Jul 2022
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
7 Best Biotech Stocks to Buy in July 2022
07:35am, Friday, 08'th Jul 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
01:09pm, Thursday, 07'th Jul 2022
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
04:05pm, Tuesday, 05'th Jul 2022
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
01:13pm, Tuesday, 05'th Jul 2022
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:45am, Friday, 01'st Jul 2022
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Biotech Stocks That Could Make You Richer
06:45am, Sunday, 26'th Jun 2022
These two companies have moved in opposite directions this year.
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
01:55pm, Wednesday, 22'nd Jun 2022
Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies
01:07pm, Friday, 17'th Jun 2022
Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.
